Antonelli, L. R. et al. The immunology of Plasmodium vivax malaria. Immunol. Rev. 293, 163–189 (2020).

Article  CAS  PubMed  Google Scholar 

World Health Organization. World Malaria Report 2023 (WHO, 2023).

Singh, B. et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363, 1017–1024 (2004).

Article  PubMed  Google Scholar 

Millar, S. B. & Cox-Singh, J. Human infections with Plasmodium knowlesi–zoonotic malaria. Clin. Microbiol. Infect. 21, 640–648 (2015).

Article  CAS  PubMed  Google Scholar 

Cheaveau, J. et al. Asymptomatic malaria in the clinical and public health context. Expert Rev. Anti Infect. Ther. 17, 997–1010 (2019).

Article  CAS  PubMed  Google Scholar 

Shretta, R. et al. in Disease Control Priorities: Major Infectious Diseases 3rd edn, Vol. 6 315–346 (World Bank Publications, 2017).

Fowkes, F. J. I., Davidson, E., Moore, K. A., McGready, R. & Simpson, J. A. The invisible burden of malaria-attributable stillbirths. Lancet 395, 268 (2020).

Article  PubMed  Google Scholar 

Bardaji, A. et al. Impact of malaria at the end of pregnancy on infant mortality and morbidity. J. Infect. Dis. 203, 691–699 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Katz, J. et al. Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. Lancet 382, 417–425 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Gallup, J. L. & Sachs, J. D. The economic burden of malaria. Am. Soc. Trop. Med. Hyg. 64, 85–96 (2001).

UNRIC. Malaria: a disease of poverty. UNRIC https://unric.org/en/malaria-a-disease-of-poverty/ (2023).

Sachs, J. & Malaney, P. The economic and social burden of malaria. Nature 415, 680–685 (2002).

Article  CAS  PubMed  Google Scholar 

Woodrow, C. J. & White, N. J. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol. Rev. 41, 34–48 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. Global Database on Antimalarial Drug Efficacy and Resistance (WHO, accessed 1 October 2023); https://www.who.int/teams/global-malaria-programme/case-management/drug-efficacy-and-resistance/antimalarial-drug-efficacy-database.

World Health Organization. Global Report on Insecticide Resistance in Malaria Vectors: 2010–2016 (WHO, 2018).

Russell, T. L., Beebe, N. W., Cooper, R. D., Lobo, N. F. & Burkot, T. R. Successful malaria elimination strategies require interventions that target changing vector behaviours. Malar. J. 12, 56 (2013).

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Mosquito on the move: a new WHO initiative takes aim at Anopheles stephensi, an invasive malarial mosquito species that thrives in cities and is expanding across Africa. WHO https://www.who.int/news-room/feature-stories/detail/mosquito-on-the-move (2022).

World Health Organization. Malaria Eradication: Benefits, Future Scenarios & Feasibility (WHO, 2020).

World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk. WHO https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk (2021).

RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).

Article  Google Scholar 

RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863–1875 (2011).

Article  Google Scholar 

Wadman, M. First malaria vaccines slashes early childhood mortality. Science https://www.science.org/content/article/first-malaria-vaccine-slashes-early-childhood-deaths (2023).

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out. University of Oxford https://www.ox.ac.uk/news/2023-10-02-oxford-r21matrix-m-malaria-vaccine-receives-who-recommendation-use-paving-way-global (2023).

Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533–544 (2024).

Article  CAS  PubMed  Google Scholar 

Half a million children die of malaria every year. Finally we can change that. Nature 622, 218 (2023).

Graumans, W., Jacobs, E., Bousema, T. & Sinnis, P. When is a Plasmodium-infected mosquito an infectious mosquito? Trends Parasitol. 36, 705–716 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baer, K., Klotz, C., Kappe, S. H., Schnieder, T. & Frevert, U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog. 3, e171 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Vaughan, A. M. et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Invest. 122, 3618–3628 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sturm, A. et al. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313, 1287–1290 (2006).

Article  CAS  PubMed  Google Scholar 

Dondorp, A. M. et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2, e204 (2005).

Article  PubMed  PubMed Central  Google Scholar 

Hirai, M. in Sexual Reproduction in Animals and Plants (eds Sawada, H., Inoue, N. & Iwano, M.) Ch. 27 (Springer, 2014).

Kappe, S. H., Kaiser, K. & Matuschewski, K. The Plasmodium sporozoite journey: a rite of passage. Trends Parasitol. 19, 135–143 (2003).

Article  PubMed  Google Scholar 

Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576–1585 (1995).

Article  CAS  PubMed  Google Scholar 

Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336, 86–91 (1997).

Article  CAS  PubMed  Google Scholar 

Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385, 803–814 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyke, K. E. et al. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect. Dis. 23, 578–588 (2023).

Article  CAS  PubMed  Google Scholar 

Wu, R. L. et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N. Engl. J. Med. 387, 397–407 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sirima, S. B. et al. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria. Sci. Transl. Med. 14, eabj3776 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498–509 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377–389 (2022).

Article  CAS  PubMed  Google Scholar 

Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475–480 (2011).

Article  CAS  PubMed